Extrapyramidal symptoms are side effects induced by antipsychotic drugs affect patient movement and include muscle rigidity, parkinsonism, akinesia (inability to initiate movement) and akathisia (inability to remain motionless), among others. This information provided by the new method helps doctors identify the most appropriate treatment for each patient, since the side effects are a major cause of abandonment of such treatments.
This technology will be incorporated into Neurofarmagen, a genetic test developed by AB-Biotics which identifies most optimum medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing their DNA, extracted from a sample of saliva. Neurofarmagen is currently marketed in Spain, through Almirall; in Brazil, through GlaxoSmithKline, and Mexico, through Scienta Farma.
More information in www.ab-biotics.com